LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

Strona główna・Stock List・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Closed

3.41 3.02

Buy Sell

Overview

Share price change

24h

Current

Min

3.41

Max

3.41

Key metrics
By Trading Economics
Income	5.5M -28M
Sales	8.2M 13M
Profit margin	-208.694
Employees	172
EBITDA	8.7M -27M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+348.25% upside

Dividends
By Dow Jones
Next Earnings	10 mar 2026

Market Stats
By TradingEconomics
Market Cap	-66M 188M
Previous open	0.39
Previous close	3.41

Technical Score

By Trading Central

Confidence

Bearish Evidence

3.17 / 3.4644 Support & Resistance

Voyager Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

19 lut 2026, 23:47 UTC

Market Talk

Global Equities Roundup: Market Talk

19 lut 2026, 23:47 UTC

Market Talk

Nikkei May Decline Amid Caution Over Potential U.S. Strike on Iran -- Market Talk

19 lut 2026, 23:39 UTC

Acquisitions, Mergers, Takeovers

Swiss Re Corporate Solutions to Buy QBE Insurance's Global Trade Credit and Surety Business >SREN.EB

19 lut 2026, 23:38 UTC

Earnings

Samsung Fire & Marine Insurance 2025 Net KRW2.020T Vs. Net KRW2.077T >000810.SE

19 lut 2026, 23:38 UTC

Earnings

Samsung Fire & Marine Insurance 2025 Oper Pft KRW2.659T Vs. Pft KRW2.650T >000810.SE

19 lut 2026, 23:38 UTC

Earnings

Samsung Fire & Marine Insurance 2025 Rev KRW24.779T Vs. KRW22.657T >000810.SE

19 lut 2026, 23:37 UTC

Market Talk

Gold Edges Lower on Possible Position Adjustment -- Market Talk

19 lut 2026, 23:34 UTC

Earnings

Samsung Fire & Marine Insurance 4Q Net Profit Missed FactSet-Compiled Consensus

19 lut 2026, 23:34 UTC

Earnings

Samsung Fire & Marine Insurance 4Q Net KRW234.38B Vs. Net KRW207.88B >000810.SE

19 lut 2026, 23:33 UTC

Earnings

Samsung Fire & Marine Insurance 4Q Oper Pft KRW391.26B Vs. Pft KRW252.81B >000810.SE

19 lut 2026, 23:33 UTC

Earnings

Samsung Fire & Marine Insurance 4Q Rev KRW6.083T Vs. KRW6.297T >000810.SE

19 lut 2026, 22:13 UTC

Market Talk

Goodman's Lack of Earnings Upgrade 'Largely Timing Related' -- Market Talk

19 lut 2026, 22:08 UTC

Earnings

Fairfax Financial 4Q Rev $8.11B >FFH.T

19 lut 2026, 22:07 UTC

Earnings

Eldorado Gold 4Q EPS $1.19 >ELD.T

19 lut 2026, 22:06 UTC

Earnings

Centerra Gold: 2026 Consolidated Gold Production Expected 250,000 to 280,000 Ounces, Copper Production Expected 50M to 60M Pounds >CG.T

19 lut 2026, 22:05 UTC

Earnings

Eldorado Gold 4Q Adj EPS 63c >ELD.T

19 lut 2026, 22:05 UTC

Earnings

Eldorado Gold 4Q Rev $577.2M >ELD.T

19 lut 2026, 22:04 UTC

Earnings

Eldorado Gold 4Q Gold Sales 126,923 Ounces >ELD.T

19 lut 2026, 22:04 UTC

Earnings

Eldorado Gold 4Q Gold Production 123,416 Ounces >ELD.T

19 lut 2026, 21:50 UTC

Market Talk

Earnings

Tech, Media & Telecom Roundup: Market Talk

19 lut 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

19 lut 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

19 lut 2026, 21:43 UTC

Earnings

St Barbara 1H Underlying Profit A$1.3 Million Vs A$48.1 Million Loss Year Earlier

19 lut 2026, 21:42 UTC

Acquisitions, Mergers, Takeovers

Palo Alto Networks Announces Offer to Purchase Relating to CyberArk Software Ltd.'s 0.00% Convertible Senior Notes Due 2030

19 lut 2026, 21:42 UTC

Earnings

St Barbara 1H Revenue A$128.8 Million, Up 32% On-Year

19 lut 2026, 21:41 UTC

Earnings

Correct: St Barbara 1H Net Loss A$249,000

19 lut 2026, 21:40 UTC

Earnings

St Barbara 1H Net Loss A$249 Million

19 lut 2026, 21:39 UTC

Earnings

Perseus Mining Reaffirms FY26 Production, AISC Guidance

19 lut 2026, 21:37 UTC

Earnings

These Stocks Are Today's Movers: Walmart, Occidental, Klarna, Wayfair, Deere, Omnicom, EPAM, and More -- Barrons.com

19 lut 2026, 21:37 UTC

Earnings

Century Aluminum Expects 1Q Adj EBITDA $215 M to $235 M >CENX

Peer Comparison

Price change

Voyager Therapeutics Inc Forecast

Price Target

By TipRanks

348.25% upside

12 Months Forecast

Average 15.33 USD 348.25%

High 25 USD

Low 10 USD

Based on 3 Wall Street analysts offering 12 month price targets forVoyager Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

3 ratings

Buy

Hold

Sell

Based on 3 analysts giving stock ratings to Voyager Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

3.17 / 3.4644Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.